Gland Pharma Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹1,834 Cr +23.3% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
GP

Gland Pharma

Q3 FY26Pharmaceuticals & Biotechnology

Gland Pharma Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹1,695Cr
+22.5% YoY
+14% QoQ
Net profit
₹261Cr
+27.3% YoY
+41.8% QoQ
Margin
26%
0 pp YoY
+5 pp QoQ
Price₹2,825
Market cap₹46.5K Cr
P/E40.6

The short version

Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business. - Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S. - Dalba is approved in 6 European countries and launched in December; U.S. Gland Pharma targets a 15% organic CAGR over the next 5 years for base business growth.

From Gland Pharma's Q3 FY26 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business.
  • Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S.
  • Dalba is approved in 6 European countries and launched in December; U.S. approval expected in February, pending additional data submission.
  • Additional demand from Europe expected to offset potential shortfalls in the U.S. Dalba launch.
  • Cenexi shows strong momentum with 14%-21% revenue growth in FY ’26 and plans capacity expansions; aiming to maintain positive EBITDA and medium- to long-term growth.
  • Capacity constraints in lyophilizers and liquid vials likely within 1-1.5 years, with ongoing investments to support volume growth.

2 more points from Gland Pharma's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Gland Pharma said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Planned capex of approximately INR 2,000 crores over the next 5 years focused on:
  • Brownfield expansions including new lines, lyophilizers, and additional warehouse capacity.
  • Investment in BFS (Blow-Fill-Seal) technology lines.
  • New ophthalmic line with suspension capability.
  • Capex towards CDMO contracts.
  • Next year capex expected to be more than INR 400 crores.
  • Asset turn targeted at more than 3x due to high-value business expectations.
  • Expansion driven by:
  • Increased demand and expected growth.
  • Current capacity constraints in lyophilizers and ophthalmic products.
  • Need to stay ahead in emerging technology platforms (BFS).

2 more points from Gland Pharma's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Gland Pharma said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Gland Pharma is experiencing higher volumes in the U.S., about 19% year-on-year increase, driven by new contracts signed, including GPO contracts.
  • The company is in discussions with insulin manufacturers for significant orders to utilize the 40 million capacity pen cartridge line.
  • For the new 100 million capacity line, expected to be ready by Q2 after validation, the existing signed contracts are sufficient to fill the capacity.
  • There's a focus on CDMO contracts with commercial quantities and take-or-pay agreements, indicating clear revenue visibility over 2-3 years.
  • Cenexi's annualized revenue is around EUR 200 million, with positive EBITDA expected going forward.

2 more points from Gland Pharma's call on order book

Create a free account to keep reading this call

Gland Pharma — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Gland Pharma Q3 FY26 results — key figures

Gland Pharma Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue1,6951,384+22.5%1,487+14%
Operating profit (EBITDA)435360+20.8%314+38.5%
Operating margin26%26%0 pp21%+5 pp
Profit before tax362299+21.1%284+27.5%
Net profit (PAT)261205+27.3%184+41.8%
EPS (₹)15.8712.42+27.8%11.15+42.3%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.8K Cr, net profit ₹291 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Natural Capsules (Q3 FY26)

    Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks

  • Wanbury (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Gujarat Themis Biosyn (Q3 FY26)

    43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q3 FY26)

    Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Gland Pharma and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Gland Pharma Q3 FY26 results?

Company expects overall growth of 12%-13% as a minimum confidence level for FY '27 base business. - Mid-teens growth (around 15%) guidance remains, contingent on product launches and regulatory approvals, especially for Dalba in the U.S. - Dalba is approved in 6 European countries and launched in December; U.S. Gland Pharma targets a 15% organic CAGR over the next 5 years for base business growth.

What is Gland Pharma share price analysis?

Gland Pharma currently shows a neutral. The stock trades at a P/E of 40.6 with a market cap of ₹46,509 Cr. Investors should review the full earnings analysis for detailed insights.

Is Gland Pharma planning capital expenditure?

Planned capex of approximately INR 2,000 crores over the next 5 years focused on: - Brownfield expansions including new lines, lyophilizers, and additional warehouse capacity.

Keep Gland Pharma on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.